Full Press Release Details
arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States.
ARGX
arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States
Key Takeaway: arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis